{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 32 of 92', 'CR845-CLIN3102', '6.2', 'Selection of Study Population', 'Patients with ESRD receiving hemodialysis 3 times a week and experiencing', 'moderate-to-severe pruritus will be considered for participation in this study.', 'A screening log of potential study candidates will be maintained at each study site.', 'Patients providing informed consent will be screened for inclusion in the study. All', 'eligibility criteria must be met before a patient is randomized.', 'Rescreening will be considered on an individual patient basis and must first be approved', 'by the Sponsor.', '6.2.1', 'Inclusion Criteria', 'To be eligible for inclusion into the Double-blind Phase of the study, a patient must meet', 'the following criteria:', '1. Willing and able to provide written informed consent prior to participating in this', 'study;', '2. Able to communicate clearly with the Investigator and staff, able to understand the', 'study procedures, and able and willing to comply with the study requirements;', '3. Male or female 18 years of age or older;', '4. Has ESRD and has been on hemodialysis 3 times per week for at least 3 months', 'prior to the start of screening;', 'Note 1: Patients who require an occasional additional dialysis treatment to', 'manage fluid overload may be enrolled as long as it is anticipated that no more', 'than 1 such treatment will be required in any given week.', 'Note 2: Patients receiving in-home hemodialysis may participate as long as they', 'have switched to in-center hemodialysis at least 2 weeks prior to screening and', 'plan to remain on in-center hemodialysis for the duration of the study.', '5. If female, is not pregnant or nursing during any period of the study;', '6. If female:', 'a.', 'Is surgically sterile; or', 'b. Has been amenorrhoeic for at least 1 year and is over the age of 55 years;', 'or', 'c. Has a negative serum pregnancy test at screening and agrees to use', 'acceptable contraceptive measures (eg, hormonal contraceptives, barrier', 'with spermicide, intrauterine device, vasectomized partner, or abstinence)', 'from the time of informed consent until 7 days after the last dose of study', 'drug;', '7. If male, agrees not to donate sperm after the first dose of study drug until 7 days', 'after the last dose of study drug, and agrees to use a condom with spermicide or', 'abstain from heterosexual intercourse during the study until 7 days after the last', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 34 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 33 of 92', 'CR845-CLIN3102', 'dose of study drug. (Note: No restrictions are required for a vasectomized male', 'provided his vasectomy was performed >4 months prior to screening);', '8. Has a prescription dry body weight between 40.0 and 135.0 kg, inclusive;', '9.', 'Has at least 2 single-pool Kt/V measurements 1.2, or at least 2 urea reduction', 'ratio measurements >65%, or 1 single-pool Kt/V measurement >1.2 and 1 urea', 'reduction ratio measurement >65% on different dialysis days during the 3 months', 'period prior to screening;', '10. Prior to randomization:', 'a.', 'Has completed at least 4 Worst Itching Intensity NRS worksheets from the', 'start of the 7-day Run-in Period up to and including the pre-randomization', 'assessment on Day 1;', 'b. Has a mean baseline Worst Itching Intensity NRS score >4, defined as the', 'average of all non-missing scores reported from the start of the 7-day', 'Run-in Period up to and including the pre-randomization assessment on', 'Day 1.', 'To be eligible for inclusion into the Open-label Extension Phase of the study, each', 'patient will have to fulfill the additional following criteria at the time of entry into', 'the Open-label Extension Phase:', '11. Has received at least 30 doses of the planned 36 doses of study drug during the', 'Double-blind Phase of this study;', '12. Has a prescription dry body weight >40 kg;', '13. Continues to meet inclusion criteria 1 through 7.', '6.2.2', 'Exclusion Criteria', 'A patient will be excluded from the Double-blind Phase of the study if any of the', 'following criteria are met:', '1.', 'Known noncompliance with dialysis treatment that in the opinion of the', 'investigator would impede completion or validity of the study;', '2. Scheduled to receive a kidney transplant during the study;', '3. Known history of allergic reaction to opiates, such as hives (Note: side effects', 'related to the use of opioids, such as constipation or nausea, would not exclude', 'patients from the study);', '4. Has a concomitant disease or a history of any medical condition that, in the', 'opinion of the Investigator, could pose undue risk to the patient, impede', 'completion of the study procedures, or would compromise the validity of the', 'study measurements, including, but not limited to:', 'a.', 'Known or suspected history of alcohol, narcotic, or other drug abuse, or', 'substance dependence within 12 months prior to screening;', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 35 of 95']\n\n###\n\n", "completion": "END"}